Sale Of Products was Vyome Holdings’s largest product and service line in fiscal 2025, bringing in $174.65K of $319.71K (55%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Sale Of Products | $134.40K | $174.65K |
| Licensing & Milestone Fees – Luliconazole | — | $116.90K |
| Service Fee For Arrangements For Sale Of Dandruff Products | $75.15K | — |
| Royalty Income Related To Above Product Sales | $47.40K | $28.17K |
| Total | $256.94K | $319.71K |
Vyome Holdings brought in $319.71K from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Vyome Holdings regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $256.94K. Sale Of Products was the largest at $174.65K (54.6%), ahead of Licensing & Milestone Fees – Luliconazole at $116.90K (36.6%) and Royalty Income Related To Above Product Sales at $28.17K (8.8%).
Compared with fiscal 2024, Sale Of Products grew 29.9% to $174.65K, while Royalty Income Related To Above Product Sales fell 40.6% to $28.17K.
Vyome Holdings began breaking out Licensing & Milestone Fees – Luliconazole in fiscal 2025, when it brought in $116.90K. Vyome Holdings stopped reporting Service Fee For Arrangements For Sale Of Dandruff Products as a separate line after fiscal 2024, when it brought in $75.15K.
United States was Vyome Holdings’s largest region in fiscal 2023, bringing in $7.13M of $8.68M (82%).
| Geography | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
|---|---|---|---|---|
| United States | $8.28M | $10.30M | $9.23M | $7.13M |
| Europe | $1.82M | $2.13M | $1.25M | $956.00K |
| Australia | $1.09M | $1.04M | $688.00K | $526.00K |
| Rest Of World | $114.00K | $137.00K | $70.00K | $62.00K |
| Total | $11.30M | $13.60M | $11.24M | $8.68M |
Vyome Holdings brought in $8.68M from its four regions in fiscal 2023, the year ended December 31, 2023. That was down 22.8% from $11.24M in fiscal 2022. United States was the largest at $7.13M (82.2%), ahead of Europe at $956.00K (11.0%) and Australia at $526.00K (6.1%). The remaining region, Rest Of World, brought in $62.00K.
Compared with fiscal 2022, every region above 2% of revenue shrank. United States held up best, down 22.7% to $7.13M, and Europe fell the most, down 23.6% to $956.00K. From fiscal 2020 to 2023, combined revenue from these regions fell from $11.30M to $8.68M, a compound annual decline of 8.4%. United States' share of the total rose from 73.2% to 82.2%.
Vyome Holdings (HIND) reports its revenue by product and service and by geography. In fiscal 2025, Sale Of Products was its largest product and service line, bringing in $174.65K (54.6% of the total), followed by Licensing & Milestone Fees – Luliconazole at $116.90K (36.6%).
Sale Of Products was Vyome Holdings' largest product and service line in fiscal 2025, bringing in $174.65K, or 54.6% of the $319.71K total across its three product and service lines.
United States was Vyome Holdings' largest region in fiscal 2023, bringing in $7.13M, or 82.2% of the $8.68M total across its four regions.
Every figure comes from Vyome Holdings' annual financial filings, as reported. Each line keeps the name Vyome Holdings gives it, and years follow its fiscal calendar.
Vyome Holdings' revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.